Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Gilead Seeks Approval of Preventive Use for HIV Drug, FT Says

Dec. 17 (Bloomberg) -- Gilead Sciences Inc., the California-based maker of the HIV treatment Truvada, asked the U.S. Food and Drug Administration to approve the medicine for use in preventing the disease, the Financial Times reported.

If the request is approved, Truvada could significantly boost Gilead’s sales and help prevent the spread of a disease that infects nearly 2.7 million people a year and kills 1.8 million, the newspaper reported today. The drug is currently the “backbone” of HIV treatment worldwide, the FT said.

The preventative use of Truvada could also cause problems for Gilead, such as undermining the effectiveness of the drug for current patients and triggering lawsuits by uninfected people who experience side effects or become infected, according to the article.

To contact the reporter on this story: Erik Larson in London at elarson4@bloomberg.net

To contact the editor responsible for this story: Anthony Aarons at aaarons@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.